Modern Style Guide,is a tetrapeptide with a cationic 3 + charge at physiological pH

Elamipretide, also known by its developmental codes MTP-131 and SS-31, has emerged as a significant mitochondria-targeting peptide in the realm of therapeutic research. This small peptide, specifically a synthetic tetrapeptide, is designed to address conditions characterized by mitochondrial dysfunction, a key factor in numerous chronic diseases. Its unique ability to concentrate within mitochondria makes it a promising candidate in combating disorders where cellular energy production and oxidative stress are compromised.

The core mechanism of action for MTP-131 lies in its interaction with the inner mitochondrial membrane. It acts as a cytochrome c peroxidase inhibitor and a mitochondrial cardiolipin binder, playing a crucial role in stabilizing cardiolipin, a vital component of the inner mitochondrial membrane. This stabilization contributes to the preservation of mitochondrial structure and function. Research indicates that elamipretide (MTP-131, SS-31) can reduce mitochondrial superoxide levels and inhibit lipid peroxidation, thereby protecting cells from oxidative damage. Studies have demonstrated its capacity to reduce reactive oxygen species production and prevent mitochondrial swelling, acting as a potent mitochondria-targeting antioxidant.

The therapeutic potential of MTP 131 is being explored across a spectrum of conditions. Pre-clinical studies have shown its efficacy in reducing infarct size in cases of myocardial infarction and improving renal function. Furthermore, elamipretide (MTP-131) has shown promise in improving mitochondrial dysfunction, as well as synaptic and memory impairment induced by various insults. Its restorative effects on mitochondrial superoxide levels have been observed to protect against the progression of diabetic kidney disease in animal models.

Among the specific applications being investigated, elamipretide is recognized as a medication for the treatment of Barth syndrome, a rare genetic disorder affecting the heart and skeletal muscles, which is often linked to mitochondrial abnormalities. The tetrapeptide compound has demonstrated the ability to improve left ventricular and mitochondrial function in preclinical models.

The chemical structure of elamipretide is a tetrapeptide with a cationic 3+ charge at physiological pH, facilitating its selective accumulation. Specifically, the amino acid sequence is often described as D-Arg-dimethylTyr-Lys-Phe-NH2. This unique composition allows it to concentrate significantly within the inner mitochondrial membrane, reportedly over 1,000-fold. The availability of MTP-131 raw powder is crucial for ongoing research and development.

Beyond its direct impact on mitochondria, elamipretide also supports mitochondrial energy production, enhances ATP production, and promotes overall cellular health. Its ability to penetrate cell membranes and enter the mitochondria underscores its targeted therapeutic approach. The research surrounding SS-31 (Elamipretide) suggests its broad applicability in addressing disorders characterized by compromised mitochondrial health. As research continues, the full therapeutic scope of this mitochondria-targeting peptide is expected to expand, offering new avenues for treating a range of debilitating conditions.